December 07, 2009 06:00 ET

MedClean Technologies (OTC: MCLN) Has Rare Opportunity to Emerge as Breakout Player in the Multi-Billion Dollar Regulated Medical Waste Market

LOS ANGELES, CA--(Marketwire - December 7, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special interview with the management team from MedClean Technologies (OTCBB: MCLN).

Last week, BioMedReports readers were introduced to MedClean Technologies, a company who provides on-site treatment solutions and fixed installations that fit within healthcare institutions while saving those hospitals and clinics a great deal of money, paperwork and resources usually allocated towards the handling of medical waste.

"Based on the interviews, company filings and financial results, we see that the experienced management team of this company is doing an outstanding job of securing a position that provides a base for further advancement in this lucrative, yet equally competitive regulated medical waste sector where company shares often trade at 14-25x earnings," writes M.E. Garza of BioMedreports. "It became very clear to us that shares of the company are trading at a vastly undervalued price point and that this is a tremendous opportunity for serious investors to consider."

As MedClean's Chairman Scott Grisanti points out during the exclusive interview, "The market opportunity in the U.S. medical waste market is two billion dollars a year... Without a doubt, there is tremendous opportunity in this market for onsite treatment of regulated medical waste, even if you set aside for a moment the HIPPA compliant destruction of confidential documents.

"Several billion dollars a year are spent in the offsite hauling of regulated medical waste, so there is tremendous market opportunity. So the companies in the market for onsite treatment of waste are small and fragmented. The good news in this is that it is a largely untapped market. So this is a multibillion dollar market opportunity that renews every year. The hospitals never stop making infectious waste. So, it is a very underpenetrated market and no company has emerged with the capability and scalability to be a significant player and we need to be that significant player."

The complete interview is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556